Skip to Content

Jardiance Approval History

Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Development History and FDA Approval Process for Jardiance

Dec  2, 2016Approval FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes
Aug  1, 2014Approval FDA Approves Jardiance (empagliflozin) to Treat Type 2 Diabetes
Jun 17, 2014Boehringer Ingelheim and Eli Lilly and Company Announce Resubmission of NDA for Empagliflozin to FDA
Mar  5, 2014U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin
Mar 29, 2013Boehringer Ingelheim, Lilly Submit NDA for Empagliflozin

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.